AMG 747

Drug Profile

AMG 747

Alternative Names: AMG747

Latest Information Update: 01 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Acetic acids; Antipsychotics; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 17 Feb 2014 Discontinued - Phase-II for Schizophrenia in Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russia, Singapore, Spain, United Kingdom and USA (PO) prior to February 2014
  • 14 Jun 2013 Amgen terminates two phase II trials in Schizoprenia in the USA, Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russian, Singapore, Spain and the United Kingdom (NCT01568229; NCT01568216)
  • 09 May 2013 Phase-II clinical trials in Schizophrenia in United Kingdom, Singapore, Malaysia, Russia, Poland, Spain, France, Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top